OTRIZOL-DF

nasal spray 0.1% with menthol and eucalyptus, 10 ml

Dispensing conditions: NO PRESCRIPTION 

Фарм.тобы: Nasal preparations

THERAPEUTIC INDICATIONS:

  • to relieve nasal congestion associated with colds, allergic rhinitis (including hay fever), sinusitis. 

dwld Download instructions for use

 

Composition

100 ml of the product contains:

  • active substance - xylometazoline hydrochloride 0.1 g;
  • excipients - sodium dihydrophosphate dihydrate, dodecahydrate phosphate dihydrate, sodium chloride, benzalkonium chloride, edetate dihydrate, levomenthol, cineol, sorbitol, liquid crystallizer 70%, castor oil, polyoxyl hydrogenated (Cremophor RH 40), purified water.

Pharmaceutical form

Nasal spray 0.1% with menthol and eucalyptus, 10 ml

Pharmacotherapeutic group

Medications for respiratory system diseases. Nasal preparations. Anticongestants and other nasal medications for topical use. Sympathomimetics. Xylometazoline.

ATC code R01AA07

Therapeutic indications

  • To relieve nasal congestion associated with colds, allergic rhinitis (including hay fever), sinusitis.

Contraindications

  • hypersensitivity to xylometazoline or any other component of the product;
  • atrophic rhinitis;
  • closed angle glaucoma;
  • surgical interventions on the cerebral membranes (history);
  • hyperthyroidism;
  • pronounced atherosclerosis;
  • arterial hypertension;
  • tachycardia;
  • severe eye diseases;
  • pregnancy, lactation period;
  • concomitant use of monoamine oxidase inhibitors and a period of up to 14 days after the end of their use;
  • children under 12 years of age.

With caution:

  • diabetes mellitus;
  • porphyria
  • prostatic hyperplasia;
  • pheochromacytoma.

Posology and method of administration

Intranasally.

Adults and children over 12 years of age: 1 injection into each nasal passage at intervals of 8-10 hours.

Do not use more than 3 times a day, and do not use more than 10 days.

Adverse reactions

Common:

  • headache;
  • with frequent or prolonged use, irritation or dryness of nasal mucosa, nasal mucous atrophy, burning, sneezing, dependence, hypersecretion, chronic rhinitis are possible.

Uncommon:

  • palpitations, tachycardia, arrhythmias, increased blood pressure;
  • nausea;
  • insomnia;
  • allergic reaction (Quincke's edema, urticaria, itching);
  • depression (with prolonged use of high doses);
  • swelling of the nasal mucosa;
  • visual impairment.

Very rare:

  • agitation;
  • fatigue, drowsiness, lethargy.

Overdose

Symptoms: anxiety, agitation, hallucinations and seizures; hypothermia, lethargy, somnolence, coma; miosis, mydriasis, increased sweating, fever, pale skin, cyanosis, nausea and vomiting, tachycardia, bradycardia, cardiac arrhythmia, cardiac arrest, palpitation, hypertension, shock-like hypotension, pulmonary edema, respiratory depression and apnea, psychiatric disorders. 

Use during pregnancy or breastfeeding

Contraindicated.

Pediatric population

Approved for children over 12 years of age.

Special warnings

Do not independently exceed the recommended doses and use the product continuously for more than 10 days.

Prolonged (more than 10 days) or excessive use of the product may cause a "ricochet" effect (medicated rhinitis).

Use with caution in coronary heart disease (CHD). 

Presentation and package

10 ml of the product is placed in brown plastic bottles with a spray nozzle and a protective cap. 1 bottle with instructions for use in the state and Russian languages are placed in a carton pack.

Storage conditions

Store in a place protected from light, at a temperature below 250С.

Keep out of the reach of children.

Shelf life

2 years and 6 months.

Manufacturer

"DOSFARM" LLP, 3 Chaplygin street, Almaty city, 050034, Kazakhstan, tel.: (727) 253-03-88.

Marketing authorization holder

"DOSFARM" LLP, 3 Chaplygin street, Almaty city, 050034, Kazakhstan.

Name, address, contact information of the organization accepting claims (proposals) against quality of products from consumers in the territory of the Republic of Kazakhstan, which is responsible for post-authorization safety surveillance of the medicine:

"DOSFARM" LLP, 3 Chaplygin street, Almaty city, 050034, Kazakhstan,

Tel./Fax: (727) 253-07-07, 253-03-88, e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра.

Осы препаратқа сұрақ қою